Literature DB >> 33627334

Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials.

Emily Herrett1, Elizabeth Williamson2, Kieran Brack3, Danielle Beaumont3, Alexander Perkins2, Andrew Thayne3, Haleema Shakur-Still3, Ian Roberts3, Danielle Prowse3, Ben Goldacre4, Tjeerd van Staa5, Thomas M MacDonald6, Jane Armitage7, Jon Wimborne8, Paula Melrose8, Jayshireen Singh9, Lucy Brooks10, Michael Moore11, Maurice Hoffman12, Liam Smeeth1.   

Abstract

OBJECTIVE: To establish the effect of statins on muscle symptoms in people who had previously reported muscle symptoms when taking statins.
DESIGN: Series of randomised, placebo controlled n-of-1 trials.
SETTING: Primary care across 50 sites in the United Kingdom, December 2016 to April 2018. PARTICIPANTS: 200 participants who had recently stopped or were considering stopping treatment with statins because of muscle symptoms.
INTERVENTIONS: Participants were randomised to a sequence of six double blinded treatment periods (two months each) of atorvastatin 20 mg daily or placebo. MAIN OUTCOME MEASURES: At the end of each treatment period, participants rated their muscle symptoms on a visual analogue scale (0-10). The primary analysis compared symptom scores in the statin and placebo periods.
RESULTS: 151 participants provided symptoms scores for at least one statin period and one placebo period and were included in the primary analysis. Overall, no difference in muscle symptom scores was found between the statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14; P=0.40)). Withdrawals because of intolerable muscle symptoms were 18 participants (9%) during a statin period and 13 (7%) during a placebo period. Two thirds of those completing the trial reported restarting long term treatment with statins.
CONCLUSIONS: No overall effect of atorvastatin 20 mg on muscle symptoms compared with placebo was found in participants who had previously reported severe muscle symptoms when taking statins. Most people completing the trial intended to restart treatment with statins. N-of-1 trials can assess drug effects at the group level and guide individual treatment. TRIAL REGISTRATION: ISRCTN30952488, EUDRACT 2016-000141-31, NCT02781064. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33627334      PMCID: PMC7903384          DOI: 10.1136/bmj.n135

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  29 in total

1.  The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?

Authors:  Andrea L Schaffer; Nicholas A Buckley; Timothy A Dobbins; Emily Banks; Sallie-Anne Pearson
Journal:  Med J Aust       Date:  2015-06-15       Impact factor: 7.738

Review 2.  Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.

Authors:  Connie B Newman; David Preiss; Jonathan A Tobert; Terry A Jacobson; Robert L Page; Larry B Goldstein; Clifford Chin; Lisa R Tannock; Michael Miller; Geetha Raghuveer; P Barton Duell; Eliot A Brinton; Amy Pollak; Lynne T Braun; Francine K Welty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-02       Impact factor: 8.311

Review 3.  Risks associated with statin therapy: a systematic overview of randomized clinical trials.

Authors:  Amir Kashani; Christopher O Phillips; JoAnne M Foody; Yongfei Wang; Sandeep Mangalmurti; Dennis T Ko; Harlan M Krumholz
Journal:  Circulation       Date:  2006-12-11       Impact factor: 29.690

4.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Authors:  Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech
Journal:  Lancet       Date:  2015-01-09       Impact factor: 79.321

5.  Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.

Authors:  Patrick M Moriarty; Terry A Jacobson; Eric Bruckert; Paul D Thompson; John R Guyton; Marie T Baccara-Dinet; Daniel Gipe
Journal:  J Clin Lipidol       Date:  2014-09-19       Impact factor: 4.766

6.  Exploring patients' reasons for discontinuance of heart medications.

Authors:  Linda Garavalia; Brian Garavalia; John A Spertus; Carole Decker
Journal:  J Cardiovasc Nurs       Date:  2009 Sep-Oct       Impact factor: 2.083

Review 7.  Interpretation of the evidence for the efficacy and safety of statin therapy.

Authors:  Rory Collins; Christina Reith; Jonathan Emberson; Jane Armitage; Colin Baigent; Lisa Blackwell; Roger Blumenthal; John Danesh; George Davey Smith; David DeMets; Stephen Evans; Malcolm Law; Stephen MacMahon; Seth Martin; Bruce Neal; Neil Poulter; David Preiss; Paul Ridker; Ian Roberts; Anthony Rodgers; Peter Sandercock; Kenneth Schulz; Peter Sever; John Simes; Liam Smeeth; Nicholas Wald; Salim Yusuf; Richard Peto
Journal:  Lancet       Date:  2016-09-08       Impact factor: 79.321

8.  Determining optimal therapy--randomized trials in individual patients.

Authors:  G Guyatt; D Sackett; D W Taylor; J Chong; R Roberts; S Pugsley
Journal:  N Engl J Med       Date:  1986-04-03       Impact factor: 91.245

9.  Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A retrospective study.

Authors:  Sangmee Sharon Bae; Buzand Oganesian; Ilana Golub; Christina Charles-Schoeman
Journal:  Clin Cardiol       Date:  2020-05-20       Impact factor: 2.882

10.  Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.

Authors: 
Journal:  Lancet       Date:  2019-02-02       Impact factor: 202.731

View more
  14 in total

1.  The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs.

Authors:  Emily Herrett; Elizabeth Williamson; Kieran Brack; Alexander Perkins; Andrew Thayne; Haleema Shakur-Still; Ian Roberts; Danielle Prowse; Danielle Beaumont; Zahra Jamal; Ben Goldacre; Tjeerd van Staa; Thomas M MacDonald; Jane Armitage; Michael Moore; Maurice Hoffman; Liam Smeeth
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

2.  Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults.

Authors:  Ciaran N Kohli-Lynch; Brandon K Bellows; Yiyi Zhang; Bonnie Spring; Dhruv S Kazi; Mark J Pletcher; Eric Vittinghoff; Norrina B Allen; Andrew E Moran
Journal:  J Am Coll Cardiol       Date:  2021-11-16       Impact factor: 24.094

Review 3.  A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms.

Authors:  Carl E Orringer; Jelani K Grant; Lale Tokgozoglu
Journal:  Curr Atheroscler Rep       Date:  2022-08-24       Impact factor: 5.967

4.  High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.

Authors:  Adam J Nelson; Kevin Haynes; Sonali Shambhu; Zubin Eapen; Mark J Cziraky; Michael G Nanna; Sara B Calvert; Kerrin Gallagher; Neha J Pagidipati; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2022-05-10       Impact factor: 27.203

Review 5.  [Statin intolerance and statin-associated muscular pain].

Authors:  Paulina Elena Stürzebecher; Friederike Schumann; Ursula Kassner; Ulrich Laufs
Journal:  Herz       Date:  2022-04-22       Impact factor: 1.740

6.  Using deep learning-based natural language processing to identify reasons for statin nonuse in patients with atherosclerotic cardiovascular disease.

Authors:  Ashish Sarraju; Jean Coquet; Alban Zammit; Antonia Chan; Summer Ngo; Tina Hernandez-Boussard; Fatima Rodriguez
Journal:  Commun Med (Lond)       Date:  2022-07-15

7.  Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Authors: 
Journal:  Lancet       Date:  2022-08-29       Impact factor: 202.731

8.  Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.

Authors:  James P Howard; Frances A Wood; Judith A Finegold; Alexandra N Nowbar; David M Thompson; Ahran D Arnold; Christopher A Rajkumar; Susan Connolly; Jaimini Cegla; Chris Stride; Peter Sever; Christine Norton; Simon A M Thom; Matthew J Shun-Shin; Darrel P Francis
Journal:  J Am Coll Cardiol       Date:  2021-09-21       Impact factor: 24.094

9.  Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.

Authors:  Alexander Hodkinson; Dialechti Tsimpida; Evangelos Kontopantelis; Martin K Rutter; Mamas A Mamas; Maria Panagioti
Journal:  BMJ       Date:  2022-03-24

10.  Tolerability of statin-based management of patients with a history of statin-associated muscle symptoms: protocol for a systematic review.

Authors:  Fanny Villoz; Christina Lyko; Cinzia Del Giovane; Nicolas Rodondi; Manuel R Blum
Journal:  BMJ Open       Date:  2021-08-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.